CD8A and neoplasm: Importantly, these cotreatments with αPD-1 antibodies and the same concentrations of either AS101 or SAS significantly increased CD8+ cell infiltration into the tumor compared with that observed in the mice treated with each of these treatments alone (Fig. 9C and Fig. S6C).